Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

Gunnar Folprecht, Claus‐Henning Köhne(Klinikum Oldenburg), Eray Goekkurt(Sorbonne Université), Jürgen Weitz(German Cancer Research Center), Ralf Konopke(University Hospital Carl Gustav Carus), Thomas Gruenberger(Medical University of Vienna), Torsten Liersch(ThyssenKrupp (Germany)), Wolf O. Bechstein(Goethe University Frankfurt), Jan Stoehlmacher(University Hospital Carl Gustav Carus), Hauke Lang(Johannes Gutenberg University Mainz), Florian Lordick(Leipzig University), Andrea Frilling(Essen University Hospital), Thomas Herrmann(Krankenhaus der Barmherzigen Brüder Trier), Fabio Parisi(New York University), Detlev Ockert(Heidelberg University), Christian Stroszczynski(University Hospital Carl Gustav Carus), Jörg T. Hartmann(University of Tübingen), Hans-Rudolf Raab(Klinikum Oldenburg)
The Lancet Oncology
November 27, 2009
10.1016/s1470-2045(09)70330-4
Cited by 960

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Gastric cancer
|The Lancet|2020|4.8k
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
Posthepatectomy liver failure: A definition and grading by the International Study Group of Liver Surgery (ISGLS)
|Surgery|2011|2.3k
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
|The Lancet|2008|1.9k